Prior Authorization Annual Review of Glumetza™ and Fortamet® FY'08

Oklahoma Health Care Authority
February 2009

Category Criteria for FY'08

Approval will be based on clinical documentation of inability to take other forms of generic metformin ER - after slow titration of 500 mg ER at 2 week intervals up to 2000 mg daily.

Product Info:
Both have an FDA Therapeutic Equivalence Code of BX and are presumed to be therapeutically **inequivalent** to other extended release metformin products currently available.

Utilization

For the 2008 fiscal year, 6,729 members received metformin products through the *SoonerCare* program.

BRAND NAME	CLAIMS	UNITS	DAYS	MEMBERS	COST	UNITS/ DAY	COST/ DAY
METFORMIN TAB 500MG	17,137	1,290,117	574,901	4,403	$ 156,517.14	2.24	$0.27
METFORMIN TAB 1000MG	8,948	612,883	312,201	2,087	$ 94,565.44	1.96	$0.30
METFORMIN TAB 500MG ER	2,052	164,790	72,291	557	$ 23,556.97	2.28	$0.33
METFORMIN TAB 850MG	1,659	118,446	56,252	413	$ 20,748.93	2.11	$0.37
METFORMIN TAB 750MG ER	176	10,426	7,381	61	$ 2,928.20	1.41	$0.40
FORTAMET TAB 1000MG	16	630	630	2	$ 2,149.18	1	$3.41
FORTAMET TAB 500MG	3	270	90	1	$ 431.98	3	$4.80
RIOMET SOL	48	21,211	1,468	18	$ 3,610.80	14.45	$2.46
GLUCOPHAGE TAB 1000MG	23	1,507	618	2	$ 2,848.45	2.44	$4.61
GLUCOPHAGE TAB XR 500MG	22	2,540	635	2	$ 2,468.13	4	$3.89
GLUMETZA TAB 500MG	9	600	275	3	$ 709.66	2.18	$2.58
GLUCOPHAGE TAB 500MG	5	500	250	1	$ 472.26	2	$1.89
Totals	**30,098**	**2,223,920**	**1,026,992**		**$311,007.14**	**2.17**	**$0.30**

Fiscal Year	Total Members	Total Claims	Total Cost	Cost per Claim	Cost per Day	Total Days
2007						
	6,017	27,690	$256,589.44	$9.27	$0.28	917,829
2008						
	6,729	30,098	$311,007.14	$10.33	$0.30	1,026,992
Percent Change	**11.8%**	**8.7%**	**21.2%**	**11.4%**	**7.1%**	**11.9%**

Total petitions received for Fortamet®/Glumetza™ during specified time period: 35

Approved *8*
Denied *14*
Incomplete *13*



Market Update

December, 2008- Generex Biotechnology Corporation announces positive results of metformin chewing gum trial (MetControl™). Currently in phase 2 trials.

Recommendations

The College of Pharmacy recommends continuation of current coverage for Fortamet® and Glumetza™.